{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:17:24Z","timestamp":1788949044736,"version":"build-2803163510"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Res"],"abstract":"<jats:p>Introduction: To systematically review the evidence from randomized controlled trials that evaluate the efficacy and safety of perfluorohexyloctane in the treatment of dry eye disease.\nMethods: Literature search was conducted on PubMed and Scopus in April 2024 with the search strategy (\"perfluorohexyloctane\" or \"NOV03\" or \"semifluorinated alkane\") and \"dry eye\". Extension and paired-eyes study were excluded. The risk of bias was assessed using the Cochrane Risk of Bias Tool. Forest plots and a summary of findings were prepared for total corneal fluorescein staining (tCFS), tear film break-up time (TFBUT), eye dryness score (EDS), and Ocular Surface Disease Index (OSDI).\nResults: The pooled standardized mean difference (SMD) for tCFS after 8 weeks of treatment was -0.53 (95% CI, -0.68 to -0.38; P&lt;0.001), indicating a significant improvement in patients treated with perfluorohexyloctane. The between-study heterogeneity was moderately high (I2=52.0%). No significant differences in TFBUT were observed (SMD=0.05; 95% CI, -0.16 to 0.25; P=0.654). Regarding symptoms, patients treated with NOV03 had significantly lower EDS compared to controls (SMD=-0.49; 95% CI, -0.66 to -0.32; P&lt;0.001), with moderately high heterogeneity (I2=71.1%). Conversely, the pooled SMD of OSDI was -0.13 (95% CI, -0.43 to 0.17; P=0.412), indicating no significant difference.\nConclusion: Perfluorohexyloctane is an effective and safe alternative for the treatment of evaporative dry eye disease due to MGD that can significantly reduce tCFS and eye dryness symptoms. More well-designed non-sponsored randomized clinical trials are required to investigate the impact on other ocular surface parameters.<\/jats:p>","DOI":"10.1159\/000542149","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T17:03:26Z","timestamp":1733245406000},"page":"1-20","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Perfluorohexyloctane for the Treatment of Patients With Dry Eye Disease: A Meta-Analysis"],"prefix":"10.1159","author":[{"given":"Andrea","family":"Taloni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Coco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Scorcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giannaccare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2024,12,2]]},"container-title":["Ophthalmic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/ore\/article-pdf\/doi\/10.1159\/000542149\/4308056\/000542149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/ore\/article-pdf\/doi\/10.1159\/000542149\/4308056\/000542149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T14:56:57Z","timestamp":1745420217000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000542149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000542149","archive":["Portico"],"relation":{},"ISSN":["0030-3747","1423-0259"],"issn-type":[{"value":"0030-3747","type":"print"},{"value":"1423-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]}}}